E-Cigarette Directories: A Qualitative Study of Perspectives From State Tobacco Control Policy Implementers
Public Health Reports® · 19.11.2026
DOI: 10.1177/00333549261502716 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift Public Health Reports®, online erschienen am 19.11.2026. Verfasst von Ginny Chadwick und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mongan Institute Health Policy Research Center and Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, MA, USA. Die Arbeit nennt 19 Literaturangaben. Gefördert von: NIDA NIH HHS, NCI NIH HHS, National Institute on Drug Abuse.
Abstract (Originalsprache)
Objectives
Bills introducing electronic cigarette (e-cigarette) directories have been filed in most US states in recent years and are quickly being adopted. This study captures the perspectives of state agency staff on these emerging, controversial tobacco control laws.
Methods
Semi-structured interviews examined the implementation of 5 e-cigarette policies: taxation, licensure, flavor restrictions, minimum legal sales age, and clean indoor air. When data on e-cigarette directories emerged during interviews, key informants (KIs) were asked follow-up questions on their perceptions about the benefits and challenges associated with directories. Data were analyzed through an iterative, team-based inductive approach. A 50-state legislative scan of tobacco (cigarettes and roll-your-own tobacco products) and e-cigarette directories was also conducted.
Results
Of 74 interviews conducted during April 2023–July 2024, directories were discussed in 12 (14 KIs, 10 states). The legislative scan (conducted from August through December 2025) identified 16 states with e-cigarette directories and 46 states with tobacco directories. KIs described e-cigarette directories as emerging tools to improve product tracking, compliance, and enforcement through fines, product seizure, and license suspension. Early implementers reported variable listing criteria, fees, and oversight. Limited staff, funding, and access to US Food and Drug Administration (FDA) data hindered enforcement. KIs expressed concerns about industry support for directories and the possibility that e-cigarette directories could advantage companies with FDA-authorized products while marginalizing smaller competitors.
Conclusions
State regulators view e-cigarette directories as a tool to curb an unfettered market, although not without disadvantages. Inclusion criteria for products are key to aligning the policies with public health goals.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mongan Institute Health Policy Research Center and Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, MA, USA.
- Heller School for Social Policy and Management, Brandeis University, Waltham, MA, USA.
- Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
- Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Ginny Chadwick, Gina R Kruse, Douglas E Levy
Förderung
- NIDA NIH HHS
- NCI NIH HHS
- National Institute on Drug Abuse
Zitieren
APA
Chadwick, G., Lee, S. C., Kahl, H. M., Stover, M., Kruse, G. R., & Levy, D. E. (2026). E-Cigarette Directories: A Qualitative Study of Perspectives From State Tobacco Control Policy Implementers. Public Health Reports®. https://doi.org/10.1177/00333549261502716
Vancouver
Chadwick G, Lee SC, Kahl HM, Stover M, Kruse GR, Levy DE. E-Cigarette Directories: A Qualitative Study of Perspectives From State Tobacco Control Policy Implementers. Public Health Reports®. 2026. doi:10.1177/00333549261502716
BibTeX
@article{Chadwick2026,
author = {Chadwick, Ginny and Lee, Sangah Clara and Kahl, Hattie M and Stover, Maeve and Kruse, Gina R and Levy, Douglas E},
title = {E-Cigarette Directories: A Qualitative Study of Perspectives From State Tobacco Control Policy Implementers},
journal = {Public Health Reports®},
year = {2026},
doi = {10.1177/00333549261502716}
}
EUVIMED